Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives.
作者： Ahmed Kaseb , Filip Janku , Manojkumar Bupathi
DOI: 10.2147/OTT.S46457
关键词:
摘要: Hepatocellular carcinoma (HCC) is a hypervascular malignancy and the third leading cause of death worldwide. The disease has multiple predisposing risk factors limited treatment options. Although precise mechanism(s) underlying HCC unknown, several pathways have been implicated in its development. vascular tumor angiogenesis believed to play an important role progression. Hypoxia increase expression endothelial growth factor (VEGF) through hypoxia-inducible factor-1α. VEGF angiopoietin 2 (Ang2) are expressed on cancer cells, whereas 1 (Ang1) occurs predominantly support cells large blood as well stromal, endothelial, cells. Ang2 concomitantly agonist antagonist during remodeling. This prevents stability allows stimulate along with growing vessels, destabilizing integrity. Inhibiting can, other hand, promote vesicular decrease angiogenesis. We discuss this review therapeutic target alone or combination therapies.
sci-hub.se 参考文章(38)
George D. Yancopoulos, Guillermo García-Cardeña, Andreas Papapetropoulos, Peter C. Maisonpierre, Thomas J. Dengler, William C. Sessa, Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Laboratory Investigation. ,vol. 79, pp. 213- 223 ,(1999)
Dervenis Ch., Pancreatic Cancer: An update Annals of Gastroenterology. ,vol. 13, ,(2007)
Qin Yu, Ivan Stamenkovic, Angiopoietin-2 Is Implicated in the Regulation of Tumor Angiogenesis The American Journal of Pathology. ,vol. 158, pp. 563- 570 ,(2001) , 10.1016/S0002-9440(10)63998-3
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme De Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner, Myron Schwartz, Camillo Porta, Stefan Zeuzem, Luigi Bolondi, Tim F Greten, Peter R Galle, Jean-François Seitz, Ivan Borbath, Dieter Häussinger, Tom Giannaris, Minghua Shan, Marius Moscovici, Dimitris Voliotis, Jordi Bruix, None, Sorafenib in Advanced Hepatocellular Carcinoma The New England Journal of Medicine. ,vol. 359, pp. 378- 390 ,(2008) , 10.1056/NEJMOA0708857
Bal Krishan Sharma, Radhika Srinivasan, Shweta Kapil, Bhupesh Singla, Nitin Saini, Yogesh Kumar Chawla, Anuradha Chakraborti, Ajay Duseja, Naveen Kalra, Radha Krishan Dhiman, Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma. Molecular and Cellular Biochemistry. ,vol. 383, pp. 103- 112 ,(2013) , 10.1007/S11010-013-1759-7
Roberta Mazzieri, Ferdinando Pucci, Davide Moi, Erika Zonari, Anna Ranghetti, Alvise Berti, Letterio S. Politi, Bernhard Gentner, Jeffrey L. Brown, Luigi Naldini, Michele De Palma, Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells Cancer Cell. ,vol. 19, pp. 512- 526 ,(2011) , 10.1016/J.CCR.2011.02.005
Napoleone Ferrara, Terri Davis-Smyth, THE BIOLOGY OF VASCULAR ENDOTHELIAL GROWTH FACTOR Endocrine Reviews. ,vol. 18, pp. 4- 25 ,(1997) , 10.1210/EDRV.18.1.0287
P. Lin, J. A. Buxton, A. Acheson, C. Radziejewski, P. C. Maisonpierre, G. D. Yancopoulos, K. M. Channon, L. P. Hale, M. W. Dewhirst, S. E. George, K. G. Peters, Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2 Proceedings of the National Academy of Sciences of the United States of America. ,vol. 95, pp. 8829- 8834 ,(1998) , 10.1073/PNAS.95.15.8829
Hedy Lee Kindler, Kathryn Bylow, Pancreatic cancer: An update Current Oncology Reports. ,vol. 9, pp. 170- 176 ,(2007) , 10.1007/S11912-007-0018-Z
Roberto Galuppo, Dinesh Ramaiah, Oscar Moreno Ponte, Roberto Gedaly, Molecular Therapies in Hepatocellular Carcinoma: What Can We Target? Digestive Diseases and Sciences. ,vol. 59, pp. 1688- 1697 ,(2014) , 10.1007/S10620-014-3058-X